RecruitingChronic Hepatitis B Infection
A Study Evaluating the Efficacy and Safety of ALG-000184 Compared With Tenofovir Disoproxil Fumarate in Untreated HBeAg-Positive and HBeAg- Negative Adult Subjects With Chronic Hepatitis B (B-SUPREME)
Eligible age
18–65 yrs
Accepts
All genders
Locations
8 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
This is a Phase 2 study to evaluate efficacy and safety of 48 weeks of oral once daily monotherapy with ALG-000184 versus tenofovir disproxil fumarate (TDF) for chronic HBV infection.
Sponsor: Aligos Therapeutics
Where it's recruiting
Arizona
Chandler
California
Coronado · Garden Grove · Los Angeles · Palo Alto …
Florida
Miami
Louisiana
Marrero
Maryland
Baltimore · Chevy Chase
Massachusetts
Boston
New York
Manhasset · New York
North Carolina
Durham
Source: ClinicalTrials.gov · NCT06963710 · last updated 2026-05-01